Literature DB >> 18185499

Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats.

Elena H Chartoff1, David Potter, Diane Damez-Werno, Bruce M Cohen, William A Carlezon.   

Abstract

Stress and chronic exposure to drugs of abuse can trigger addictive and depressive disorders. Both stimuli increase activity of dynorphin, a neuropeptide that acts at kappa-opioid receptors (KORs). In humans, KOR agonists cause dysphoria, raising the possibility that dynorphin modulates the depressive-like effects of stress and chronic drug use. We examined if KOR activation alters sensitivity to stimulant drugs by assessing the effects of the selective KOR agonist, salvinorin A (SalvA), on cocaine-induced locomotor activity and c-Fos expression. Acute administration of SalvA blocked the locomotor-stimulant effects of cocaine, whereas repeated SalvA together with concomitant exposure to activity testing chambers potentiated the locomotor response to a cocaine challenge. In contrast, repeated SalvA administered in home cages rather than the activity chambers failed to potentiate the locomotor response to a cocaine challenge. One potential explanation for these findings is that activation of KORs disrupts context conditioning: acute locomotor responses to SalvA alone did not fully habituate with repeated testing in the activity chambers. The effects of SalvA on locomotor activity paralleled its effects on cocaine-induced c-Fos expression in the dorsal striatum: acute SalvA attenuated cocaine-induced c-Fos, whereas repeated SalvA potentiated it when administered in the activity chambers but not the home cage. Acute SalvA also blocked the locomotor stimulant effects of the D1 receptor agonist SKF 82958, whereas repeated SalvA potentiated these effects when administered in the activity chambers. These findings suggest that SalvA regulates the stimulant effects of cocaine through interactions with D1 receptor-mediated signaling in the dorsal striatum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18185499      PMCID: PMC2564810          DOI: 10.1038/sj.npp.1301659

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  66 in total

1.  U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking.

Authors:  S Schenk; B Partridge; T S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  1999-06       Impact factor: 4.530

2.  Stress-induced craving and stress response in cocaine dependent individuals.

Authors:  R Sinha; D Catapano; S O'Malley
Journal:  Psychopharmacology (Berl)       Date:  1999-03       Impact factor: 4.530

3.  New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors.

Authors:  David Y W Lee; Zhongze Ma; Lee-Yuan Liu-Chen; Yulin Wang; Yong Chen; William A Carlezon; Bruce Cohen
Journal:  Bioorg Med Chem       Date:  2005-10-01       Impact factor: 3.641

4.  Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.

Authors:  Thomas A Munro; Mark A Rizzacasa; Bryan L Roth; Beth A Toth; Feng Yan
Journal:  J Med Chem       Date:  2005-01-27       Impact factor: 7.446

5.  Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine.

Authors:  John E Pintar; Toni S Shippenberg; Vladimir I Chefer; Traci Czyzyk; Elizabeth A Bolan; Jose Moron
Journal:  J Neurosci       Date:  2005-05-18       Impact factor: 6.167

6.  Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2005-01-29       Impact factor: 4.530

7.  The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum.

Authors:  A M Gray; S M Rawls; T S Shippenberg; J F McGinty
Journal:  J Neurochem       Date:  1999-09       Impact factor: 5.372

8.  Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.

Authors:  William A Carlezon; Cécile Béguin; Jennifer A DiNieri; Michael H Baumann; Michele R Richards; Mark S Todtenkopf; Richard B Rothman; Zhongze Ma; David Y-W Lee; Bruce M Cohen
Journal:  J Pharmacol Exp Ther       Date:  2005-10-13       Impact factor: 4.030

9.  Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys.

Authors:  S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

Review 10.  Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.

Authors:  Feng Yan; Bryan L Roth
Journal:  Life Sci       Date:  2004-10-15       Impact factor: 5.037

View more
  35 in total

1.  Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone.

Authors:  Yan Zhou; Rachel Saylor Crowley; Konrad Ben; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2017-03-02       Impact factor: 3.252

2.  Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats.

Authors:  S Stevens Negus; Robert O'Connell; Ember Morrissey; Kejun Cheng; Kenner C Rice
Journal:  J Pharmacol Exp Ther       Date:  2011-11-29       Impact factor: 4.030

Review 3.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 4.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 5.  Clerodane diterpenes: sources, structures, and biological activities.

Authors:  Rongtao Li; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2016-07-18       Impact factor: 13.423

6.  Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo.

Authors:  Gabriella Aviello; Francesca Borrelli; Francesca Guida; Barbara Romano; Kevin Lewellyn; Maria De Chiaro; Livio Luongo; Jordan K Zjawiony; Sabatino Maione; Angelo A Izzo; Raffaele Capasso
Journal:  J Mol Med (Berl)       Date:  2011-04-16       Impact factor: 4.599

7.  Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.

Authors:  David N Potter; Diane Damez-Werno; William A Carlezon; Bruce M Cohen; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2011-07-14       Impact factor: 13.382

Review 8.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

9.  Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats.

Authors:  Shayla E Russell; Anna B Rachlin; Karen L Smith; John Muschamp; Loren Berry; Zhiyang Zhao; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

10.  Anatomically dissociable effects of dopamine D1 receptor agonists on reward and relief of withdrawal in morphine-dependent rats.

Authors:  Elena H Chartoff; Matthew F Barhight; Steve D Mague; Allison M Sawyer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2009-01-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.